Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To demonstrate an improvement in progression-free survival (PFS) in patients with mCRC treated with sunitinib plus FOLFOX compared with bevacizumab plus FOLFOX in the first-line treatment setting.
Critère d'inclusion
- Metastatic colorectal cancer